WO2020141869A1 - Icam-1에 특이적으로 결합하는 항체 및 그의 용도 - Google Patents
Icam-1에 특이적으로 결합하는 항체 및 그의 용도 Download PDFInfo
- Publication number
- WO2020141869A1 WO2020141869A1 PCT/KR2019/018822 KR2019018822W WO2020141869A1 WO 2020141869 A1 WO2020141869 A1 WO 2020141869A1 KR 2019018822 W KR2019018822 W KR 2019018822W WO 2020141869 A1 WO2020141869 A1 WO 2020141869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- icam
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Definitions
- the present invention relates to a pharmaceutical composition for the differentiation and/or function regulation of dendritic cells comprising as a component and a pharmaceutical composition for the prevention and/or treatment of immune cell-mediated diseases.
- Dendritic cells are highly specialized antigen presenting cells that incorporate a variety of immune responses and contain a heterogeneous family of antigen presenting cells involved in the initiation of immunity and immune tolerance. To date, immature dendritic cells induce T cells into an immunodeficiency state, and dendritic cells transformed into mature dendritic cells by active stimulants such as lipopolysaccharide (LPS) induce primary T cell responses. . In addition, semi-mature dendritic cells with unique cytokine production profiles can confer immunotolerant function.
- active stimulants such as lipopolysaccharide (LPS)
- LPS lipopolysaccharide
- semi-mature dendritic cells with unique cytokine production profiles can confer immunotolerant function.
- ICAM-1 Intercellular Adhesion Molecule 1
- domain 1 to domain 5 consists of five extracellular interstitial globulin superfamily domains, cell transmembrane regions, and intracellular regions, numbered in the N- to C-terminal direction, 90 kDa is a type I cell surface glycoprotein.
- ICAM-1 mediates white blood cell/leukocyte interactions, such as the interaction between T cells and antigen presenting cells. It also mediates leukocyte outflow into tissues during the inflammatory process.
- LFA-1 ICAM-1/leukocyte function antigen-1
- enlimomab In a monkey study using R6-5-D6 (enlimomab), a mouse monoclonal antibody that binds to the domain of human ICAM-1, renal allograft survival was increased and T cell infiltration into the graft was reduced compared to control (J Immunol. 1990, 144:4604-4612). In addition, enlimomab has been demonstrated to be effective in inhibiting disease activity in patients with rheumatoid arthritis (Arthritis Rheum. 1994, 37:992-999; J Rheumatol. 1996, 23:1338-1344). However, enrimomab induction treatment after kidney transplantation has no significant effect on reducing the rate of acute rejection or risk of delayed graft function.
- Enrimomab functions to block the attachment of neutrophils to vascular endothelial cells as well as T cells, and thus it has been reported that interfering with neutrophil migration potentially increases susceptibility to infection (J Immunol. 1999, 162:2352-2357).
- One example provides an anti-ICAM-1 antibody or antigen-binding fragment thereof that specifically recognizes ICAM-1.
- the anti-ICAM-1 antibody or antigen-binding fragment thereof is provided.
- CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 (GYTFTDYA), polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2 (ISTYSGNT), and the amino acid sequence of SEQ ID NO: 3 (ARSLYFGSSGFDY)
- CDRs Complementarity Determining Regions
- CDRs comprising a polypeptide (CDR-H3) comprising or a heavy chain variable region comprising the heavy chain complementarity determining region;
- Polypeptide (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4 (QTLVYRNGNTY), polypeptide (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5 (KVS), and amino acid sequence of SEQ ID NO: 6 (SQNTHFPYT) It may be to include a light chain variable region comprising the light chain complementarity determining region or the light chain complementarity determining region comprising a polypeptide (CDR-L3) comprising a.
- the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 and 11 to 34
- the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 and 35 to 38.
- heavy chain complementarity determining region a heavy chain complementarity determining region, heavy chain variable region, or nucleic acid molecule encoding a heavy chain of an anti-ICAM-1 antibody.
- nucleic acid molecules encoding light chain complementarity determining regions, light chain variable regions or light chains of anti-ICAM-1 antibodies.
- Another example is a nucleic acid molecule encoding a heavy chain complementarity determining region, heavy chain variable region or heavy chain of the anti-ICAM-1 antibody and a nucleic acid molecule encoding a light chain complementarity determining region, light chain variable region or a light chain of the anti-ICAM-1 antibody.
- Recombinant vectors are provided that are included together or in separate vectors.
- Another example provides a recombinant cell comprising the recombinant vector.
- Another example provides a pharmaceutical composition for preventing and/or treating a disease comprising the anti-ICAM-1 antibody or antigen-binding fragment thereof as an active ingredient.
- the disease may be an immune cell mediated disease.
- Another example comprises the step of administering a pharmaceutically effective amount of the ICAM-1 antibody or antigen-binding fragment thereof to a subject in need of prevention and/or treatment of an immune cell-mediated disease, and And/or provide treatment.
- the method may further comprise identifying a subject in need of prevention and/or treatment of an immune cell mediated disease prior to the step of administering.
- the immune cell-mediated disease may be selected from transplant rejection, graft versus host disease, asthma, autoimmune disease, and the like.
- Another example provides a pharmaceutical composition for regulating the differentiation and/or function of dendritic cells comprising the anti-ICAM-1 antibody or antigen-binding fragment thereof as an active ingredient.
- Another example is a method of modulating the differentiation and/or function of dendritic cells, comprising administering a pharmaceutically effective amount of an anti-ICAM-1 antibody or antigen-binding fragment thereof to a subject in need thereof.
- Other examples provide use for use in the manufacture of pharmaceutical compositions for modulating the differentiation and/or function of dendritic cells or modulating the differentiation and/or function of dendritic cells of an anti-ICAM-1 antibody or antigen-binding fragment thereof.
- anti-ICAM-1 antibodies or antigen-binding fragments thereof that specifically recognize ICAM-1, and uses thereof.
- the anti-ICAM-1 antibody or antigen-binding fragment thereof is characterized by specifically recognizing and/or binding domain 2 of the domain of ICAM-1.
- the anti-ICAM-1 antibody or antigen-binding fragment thereof may be an antagonist having inhibitory activity against ICAM-1.
- the antibody does not inhibit ICAM-1/LFA-1 binding itself by binding to domain 2 rather than domain 1 of ICAM-1, which is a binding site with LFA-1, a ligand of the antigen ICAM-1. This can be confirmed through the fact that the antibody does not inhibit T cell transmigration.
- the antibody is an immune synapse for the delivery of T cell activity in that it induces differentiation into intolerant dendritic cells and induces functional immunosuppression and suppresses the immune activity of T cells in co-culture with dendritic cells and T cells. It can potentially affect spatial function activation and binding and reorganization between related proteins.
- the antibody may be an antagonist that functionally inhibits ICAM-1 activity rather than physically inhibiting receptor-ligand binding.
- the antibody may be to induce a result of suppressing the immune activity of T cells containing a ligand as a result by the above-described activity.
- the anti-ICAM-1 antibody or antigen-binding fragment thereof provided herein binds to domain 2 of ICAM-1 (eg, human ICAM-1) and induces antigen-specific T-cell resistance, thereby dendritic cells. Inhibiting the differentiation and / or function of, and may have a prophylactic and/or therapeutic effect on immune cell-mediated diseases.
- ICAM-1 eg, human ICAM-1
- ICAM-1 Intercellular Adhesion Molecule 1
- CD54 Cluster of Differentiation 54
- ICAM-1 acting as an antigen of the antibody provided herein may be of mammalian origin, such as human ICAM-1 (e.g., NCBI accession numbers NP_000192.2, etc.), monkey ICAM-1 (e.g., NCBI accession numbers NP_001266532 Etc.).
- the antibody may exhibit cross-reactivity to human ICAM-1 and monkey ICAM-1.
- the term "antibody” refers to a substance made by stimulation of an antigen in the immune system or a protein that specifically binds to a specific antigen, and is produced recombinantly or synthetically based on the substance or protein. It is also used as a concept that includes proteins.
- the antibody may be non-naturally produced, for example, recombinantly or synthetically produced.
- the antibody may be an animal antibody (eg, mouse antibody, etc.), a chimeric antibody (eg, mouse-human chimeric antibody), a humanized antibody, or a human antibody.
- the antibody can be a monoclonal antibody or a polyclonal antibody.
- an antibody herein can be understood to include all fragments of an antibody that retain antigen-binding ability, unless otherwise specified.
- complementarity-determining regions means a region that confers binding specificity with an antigen among variable regions of an antibody.
- the antigen-binding fragment of the above-described antibody may be an antibody fragment comprising one or more of the complementarity determining regions.
- One example provides an anti-ICAM-1 antibody or antigen-binding fragment thereof that specifically recognizes ICAM-1 or specifically binds ICAM-1.
- the anti-ICAM-1 antibody or antigen-binding fragment thereof is provided.
- CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 (GYTFTDYA), polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2 (ISTYSGNT), and the amino acid sequence of SEQ ID NO: 3 (ARSLYFGSSGFDY)
- CDRs Complementarity Determining Regions
- CDRs comprising a polypeptide (CDR-H3) comprising or a heavy chain variable region comprising the heavy chain complementarity determining region;
- Polypeptide (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4 (QTLVYRNGNTY), polypeptide (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5 (KVS), and amino acid sequence of SEQ ID NO: 6 (SQNTHFPYT)
- Light chain complementarity determining region comprising a polypeptide (CDR-L3) comprising or a light chain variable region comprising the light chain complementarity determining region
- Heavy chain framework 1 (VH-FR1; N-terminal flanking region of CDRH1) is SEQ ID NO: 97 (QVQLX1QSGAEX2X3X4PGX5SVKX6SCKX7S; X1 is Q or V, X2 is L or V, X3 is V or K, X4 is R or K, X5 is R or K, X5 is V or A, X6 is I or V, X7 is G or A) or amino acid sequence of SEQ ID NO: 98 (QVQLX8QSGAEVX9KPGASVKX10SCKX11S; X8 is V or Q, X9 is K or V, X10 is K or V, X10 is I or V, X11 is G or A) ,
- Heavy chain framework 2 (VH-FR2; site between the C-terminus of CDRH1 and the N-terminus of CDRH2) is SEQ ID NO: 99 (LHWVX12QX13X14X15X16X17LEWX18GV; X12 is K or R, X13 is S or A, X14 is H or P, X15 A or G, X16 is K or Q, X17 is S or R, X18 is I or M) or amino acid of SEQ ID NO: 100 (LHWVX19QAPGQX20LEWX21GV; X19 is R or K, X20 is R or S, X21 is I or M)
- a sequence may include an amino acid sequence selected from SEQ ID NOs: 49, 50, 51, 52, 53, 54, and 55,
- Heavy chain framework 3 (VH-FR3; site between the C-terminus of CDRH2 and the N-terminus of CDRH3) is SEQ ID NO: 101 (X22YX23QKFX24GX25X26TX27TX28DX29SX30X31TAYX32ELX33X34LX35SEDX36AX37X38YC; X22 is D or K, X, Is K or R, X26 is A or V, X27 is M or I, X28 is V or R, X29 is K or T, X30 is S or A, X31 is T or S, X32 is L or M, X33 is A Or S, X34 is R or S, X35 is T or R, X36 is S or T, X37 is I or V, X38 is H or Y) or SEQ ID NO: 102 (X39YX40QKFX41GX42X43TX44TX45RX46SAX47TA
- the heavy chain framework 4 (VH-FR4; the region adjacent to the C-terminus of CDRH3) may be one comprising the amino acid sequence of SEQ ID NO: 81.
- Light chain framework 1 (VL-FR1; N-terminal flanking region of CDRL1) is SEQ ID NO: 103 (DVVLTQX51PLSX52PVX53LGX54X55ASISCRSS; X51 is T or S, X52 is L or S, X53 is N or T, X54 is D or Q, X55 is Q or P) or SEQ ID NO: 104 DVVLTQX56PLSX57PVTLGQPASISCRSS; X56 is S or T, X57 is L or S) may include an amino acid sequence selected from, for example, SEQ ID NO: 82, 83, and 84,
- Light chain framework 2 (VL-FR2; site between the C-terminus of CDRL1 and the N-terminus of CDRL2) is SEQ ID NO: 105 (LHWYX58QX59X60GQX61PX62LLIX63; X58 is L or Q, X59 is K or R, X60 is A or P, X61 Silver S or P, X62 is K or R, X63 is Y or not present), for example, SEQ ID NO: 85, 86, 87, 88, and 89 may include an amino acid sequence selected from
- Light chain framework 3 (VL-FR3; site between the C-terminus of CDRL2 and the N-terminus of CDRL3) comprises the amino acid sequence of SEQ ID NO: 106 (NRFSGVPDRFSGSGX64GTDFTLKISRVEAEDX65GVYFC; X64 is S or A, X65 is L or V), e.g., sequence May comprise amino acid sequences selected from numbers 90, 91, and 93, and/or
- Light chain framework 4 (VL-FR4; the region adjacent to the C-terminus of CDRL3) is SEQ ID NO: 107 (FGGGTKX66X67X68X69X70; I or L for X66, K or E for X66, R or I for X68, Q or K for X69, X70 R or not present) may include, for example, the amino acid sequence of SEQ ID NO: 93 or 94.
- VH-FR1 comprising the amino acid sequence of SEQ ID NO: 97 or 98 (e.g., SEQ ID NO: 39, 40, 41, 42, 43, 44, 45, 46, 47, or 48) CDRH1 comprising amino acid sequence
- VH-FR2 comprising amino acid sequence of SEQ ID NO: 99 or 100 (e.g., SEQ ID NO: 49, 50, 51, 52, 53, 54, or 55), amino acid sequence of SEQ ID NO: 2 CDRH2, SEQ ID NO: 101 or 102 (e.g., SEQ ID NO: 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 , 75, 76, 77, 78, 79, or 80), including VH-FR3 comprising the amino acid sequence of SEQ ID NO: 3, CDRH3 comprising the amino acid sequence of SEQ ID NO: 3, CDRH3 compris
- the light chain variable region is VL-FR1 comprising the amino acid sequence of SEQ ID NO: 103 or 104 (e.g., SEQ ID NO: 82, 83, or 84), CDRL1 comprising the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 105 (e.g., sequence VL-FR2 comprising the amino acid sequence of SEQ ID NO: 85, 86, 87, 88, or 89, CDRL2 comprising the amino acid sequence of SEQ ID NO: 5, amino acid of SEQ ID NO: 106 (e.g., SEQ ID NO: 90, 91, or 93) VL-FR3 comprising the sequence, CDRL3 comprising the amino acid sequence of SEQ ID NO: 6, and VL-FR4 comprising the amino acid sequence of SEQ ID NO: 107 (eg, SEQ ID NO: 93 or 94).
- SEQ ID NO: 103 or 104 e.g., SEQ ID NO: 82, 83, or 84
- the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 and 11 to 34
- the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 and 35 to 38.
- Animal-derived antibodies produced by immunizing an immunized animal with a desired antigen may generally undergo an immune rejection reaction when administered to a human for therapeutic purposes, and chimeric antibodies have been developed to suppress such immune rejection.
- Chimeric antibodies are those that replace the constant regions of animal-derived antibodies that cause anti-isotype reactions with the constant regions of human antibodies using genetic engineering methods. Chimeric antibodies have been significantly improved in anti-isotype reactions compared to animal-derived antibodies, but still contain animal-derived amino acids in the variable region, thus implicating potential anti-idiotypic reactions. Doing. Humanized antibodies have been developed to improve these side effects. It is produced by transplanting a region of CDR (complementaritiy determining regions) that plays an important role in antigen binding among variable regions of a chimeric antibody into a human antibody framework.
- CDR complementaritiy determining regions
- the most important thing in the CDR grafting technology for producing humanized antibodies is to select an optimized human antibody that can best accept the CDR regions of animal-derived antibodies. To this end, use of an antibody database and crystal structure structure), and molecular modeling technology.
- the antibody may be an animal antibody (eg, mouse antibody), a chimeric antibody (eg, a mouse-human chimeric antibody) or a humanized antibody.
- animal antibody eg, mouse antibody
- chimeric antibody eg, a mouse-human chimeric antibody
- humanized antibody e.g., humanized antibody.
- the heavy chain framework and/or heavy chain constant region excluding heavy chain CDRs of SEQ ID NOs: 1 to 3 are immunoglobulins (IgG (IgG1, IgG2, IgG3, IgG4, etc.), IgM, IgA, IgD , Or IgE), e.g., human immunoglobulins (IgG (IgG1, IgG2, IgG3, IgG4, etc.), IgM, IgA, IgD, or IgE) and may be heavy chain framework and/or heavy chain constant regions.
- the light chain framework and/or light chain constant region excluding the light chain CDRs of numbers 4 to 6 may be a kappa ( ⁇ ) or lambda ( ⁇ ) type light chain framework and/or light chain constant region.
- a complete antibody has a structure having two full length light chains and two full length heavy chains, and each light chain is linked by a heavy chain and a disulfide bond.
- the constant region of the antibody is divided into a heavy chain constant region and a light chain constant region, and the heavy chain constant region has gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and epsilon ( ⁇ ) types, and subclasses.
- the constant regions of the light chain have kappa ( ⁇ ) and lambda ( ⁇ ) types.
- variable chain refers to the variable region domain V H and the three constant region domains C H1 , C H2 and C H3 and hinges (including amino acid sequences having sufficient variable region sequences to confer specificity to the antigen) ( It is interpreted as including both the full-length heavy chain and the fragments thereof.
- light chain refers to both the full-length light chain comprising the variable region domain V L and the constant region domain C L and fragments thereof comprising an amino acid sequence having sufficient variable region sequences to confer specificity to the antigen. It is interpreted as including meaning.
- CDR complementarity determining region
- the heavy chain and light chain may each include three CDRs (CDRH1, CDRH2, CDRH3 and CDRL1, CDRL2, CDRL3).
- the CDRs can provide a major contact residue for the antibody to bind to an antigen or epitope.
- specifically binding or “specifically recognized” is the same as the meaning commonly known to those skilled in the art, the antigen and the antibody specifically interact to perform an immunological reaction.
- antigen-binding fragment is a fragment of the entire structure of an immunoglobulin, meaning a portion to which an antigen can bind, such as a portion of an antibody comprising a CDR.
- the antigen-binding fragment of an antibody may be scFv, (scFv) 2 , Fab, Fab' or F(ab') 2 .
- Fab has a structure having a variable region of a light chain and a heavy chain, a constant region of a light chain, and a first constant region (C H1 ) of a heavy chain, and has one antigen-binding site.
- Fab' differs from Fab in that it has a hinge region containing one or more cysteine residues at the C-terminus of the heavy chain C H1 domain.
- the F(ab') 2 antibody is produced by cysteine residues in the hinge region of Fab' forming disulfide bonds.
- Fv is a minimal antibody fragment having only a heavy chain variable region and a light chain variable region, and recombinant techniques for generating Fv fragments are well known in the art.
- the double-stranded Fv (two-chain Fv) is a non-covalently linked heavy chain variable region and a light chain variable region
- single-stranded Fv (single-chain Fv; scFv) is generally composed of a heavy chain variable region and a single chain through a peptide linker.
- the variable region may be linked by a covalent bond or directly linked at the C-terminus to form a dimer-like structure such as a double-chain Fv.
- the antigen-binding fragment can be obtained using proteolytic enzymes (e.g., restriction digestion of the whole antibody with papain yields Fab and cleavage with pepsin yields F(ab') 2 fragment), It can be produced through genetic recombination technology.
- hinge region refers to a region contained in the heavy chain of an antibody, which exists between CH1 and CH2 regions, and functions to provide flexibility of an antigen binding site in an antibody.
- the anti-ICAM-1 antibody may be a monoclonal antibody.
- Monoclonal antibodies can be prepared by methods well known in the art. For example, it can be manufactured using a phage display technique.
- the anti-ICAM-1 antibody can be produced as a monoclonal antibody derived from an animal (eg, mouse) by conventional methods.
- ELISA Enzyme-Linked ImmunoSorbent Assay
- Inhibitory activity can be assayed through functional assays such as competitive ELISA (competitive ELISA) or cell-based assays to assay molecular interactions for conjugates.
- ELISA Enzyme-Linked ImmunoSorbent Assay
- Each affinity for ICAM-1 can then be assayed for selected monoclonal antibody members based on strong inhibitory activity.
- Another example provides a pharmaceutical composition for preventing and/or treating diseases comprising the anti-ICAM-1 antibody or antigen-binding fragment thereof as an active ingredient.
- the disease may be an immune cell mediated disease.
- Another example comprises the step of administering a pharmaceutically effective amount of the ICAM-1 antibody or antigen-binding fragment thereof to a subject in need of prevention and/or treatment of an immune cell-mediated disease, and And/or provide treatment.
- the method may further comprise identifying a subject in need of prevention and/or treatment of an immune cell mediated disease prior to the step of administering.
- Another example provides the use of the ICAM-1 antibody or antigen-binding fragment thereof for the prevention and/or treatment of immune cell-mediated diseases, or for the manufacture of pharmaceutical compositions for the prevention and/or treatment of immune cell-mediated diseases. do.
- the immune cell-mediated disease may be selected from all diseases related to immune cells.
- the immune cells may be one or more selected from the group consisting of T cells, B cells, dendritic cells, macrophage, and monocytes.
- the immune cell mediated disease is transplant rejection (e.g., allogeneic transplantation, allograft transplantation, xenograft rejection reaction occurring during transplantation), graft-versus-host disease (e.g., occurs when allogeneic bone marrow transplantation) Graft-versus-host disease, etc.), asthma, obesity, type 2 diabetes, autoimmune diseases (e.g. encephalomyelitis (e.g.
- allergic encephalomyelitis rheumatoid arthritis, systemic lupus erythematosus (loops), atopic dermatitis, multiple sclerosis, type 1 Diabetes, chronic inflammatory diseases (e.g., inflammatory growth diseases (e.g., Crohn's disease, ulcerative colitis)), Behcet's disease, Sjogren's syndrome, myasthenia gravis, scleroderma, crystalline polyarteritis, Kikuchi disease, collagen disease, Hashimoco thyroiditis, psoriasis, Vitiligo, hyperthyroidism, fibromyalgia, alopecia areata, allergies, etc., immune cells (e.g., T cells, B cells, dendritic cells, macrophages, monocytes, etc.) mediated inflammation (e.g. macrophage mediated inflammation, etc.), the immunity It may be selected from inflammatory diseases caused by cell-mediated inflammation, and the like.
- Another example provides a pharmaceutical composition for regulating the differentiation and/or function of dendritic cells comprising the anti-ICAM-1 antibody or antigen-binding fragment thereof as an active ingredient.
- Another example is a method of modulating the differentiation and/or function of dendritic cells, comprising administering a pharmaceutically effective amount of an anti-ICAM-1 antibody or antigen-binding fragment thereof to a subject in need thereof.
- Other examples provide use for use in the manufacture of pharmaceutical compositions for modulating the differentiation and/or function of dendritic cells or modulating the differentiation and/or function of dendritic cells of an anti-ICAM-1 antibody or antigen-binding fragment thereof.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is commonly used for the formulation of drugs, lactose, dextrose, sucrose, trehalose, alginy, histidine, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, 1 selected from the group consisting of calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc. 1 It may be more than a species, but is not limited thereto.
- the pharmaceutical composition may further include one or more selected from the group consisting of diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc., which are commonly used in the manufacture of pharmaceutical compositions.
- the pharmaceutical composition, or an effective amount of the antibody or antigen-binding fragment thereof may be administered orally or parenterally.
- parenteral administration intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, intranasal administration, intrapulmonary administration, rectal administration, or local administration of a lesion site may be administered.
- the protein or peptide is digested, so the oral composition can be formulated to coat the active agent or protect it from degradation in the stomach.
- the composition can be administered by any device capable of transporting the active substance to the target cell.
- “pharmaceutically effective amount” may mean a content or dosage of an active ingredient (ie, an anti-ICAM-1 antibody or antigen-binding fragment thereof) capable of exhibiting a desired pharmacological effect, and formulated.
- an active ingredient ie, an anti-ICAM-1 antibody or antigen-binding fragment thereof
- Methods, dosage regimen, patient's age, weight, sex, morbidity, food, time of administration, interval of administration, route of administration, rate of excretion and response responsiveness may vary.
- the content of the anti-ICAM-1 antibody or antigen-binding fragment thereof or the dose of the anti-ICAM-1 antibody or antigen-binding fragment thereof in the pharmaceutical composition is the method of formulation, the mode of administration, the patient's age, weight, sex, morbidity, food, It can be variously prescribed by factors such as administration time, administration interval, administration route, excretion rate and response sensitivity.
- the daily dose of the anti-ICAM-1 antibody or antigen-binding fragment thereof is 0.001 to 1000 mg/kg, specifically 0.01 to 100 mg/kg, more specifically 0.1 to 50 mg/kg, more specifically 0.1 to 20 mg/kg, but is not limited thereto.
- the daily dosage may be formulated as a single dosage form in unit dose form, or may be formulated in appropriate portions, or may be prepared by incorporating into a multi-dose container.
- the pharmaceutical composition may be administered in combination with other drugs, such as other anticancer agents, and the dosage, administration method, and type of other drugs may be appropriately prescribed according to the patient's condition.
- the pharmaceutical composition may be in the form of a solution, suspension, syrup, or emulsion in an oil or aqueous medium, or may be formulated in the form of ex-agent, powder, granule, tablet or capsule, and dispersant or stable for formulation It may further include a topic.
- the patient to which the pharmaceutical composition is administered may be a mammal including a primate such as a human or a monkey.
- the anti-ICAM-1 antibody or antigen-binding fragment thereof specifically binds ICAM-1, it is possible to detect or confirm ICAM-1 using the same.
- another example of the present invention provides a composition for the detection of ICAM-1 comprising the anti-ICAM-1 antibody or antigen-binding fragment thereof.
- Another example is processing the anti-ICAM-1 antibody or antigen-binding fragment thereof in a biological sample; And it provides a method for detecting ICAM-1 comprising the step of determining whether the antigen-antibody reaction. In the detection method, when an antigen-antibody reaction is detected, it can be determined (determined) that ICAM-1 is present in the biological sample.
- the detection method may further include determining that ICAM-1 is present in the biological sample when an antigen-antibody reaction is detected, after the step of determining whether the antigen-antibody reaction is detected.
- the biological sample may be selected from the group consisting of (separated) cells, tissues, body fluids, cultures, etc. obtained from mammals, such as humans (eg, patients to be transplanted or transplanted, patients with autoimmune diseases, etc.). .
- the step of determining whether or not the antigen-antibody reaction can be performed through various methods known in the art. For example, it can be measured through conventional enzymatic reaction, fluorescence, luminescence and/or radiation detection. Specifically, immunochromatography, immunohistochemistry, enzyme linked immunosorbent assay: ELISA), radioimmunoassay (RIA), enzyme immunoassay (EIA), fluorescence immunoassay (FIA), luminescence immunoassay (LIA), Western blotting (Western blotting) ), may be measured by a method selected from the group consisting of microarrays, but is not limited thereto.
- the heavy chain complementarity determining region, light chain complementarity determining region, or combinations thereof of the anti-ICAM-1 antibody described above; Or a polypeptide molecule comprising a heavy chain variable region, a light chain variable region, or a combination thereof is provided.
- the polypeptide molecule may be used as a precursor of an antibody, and may be used as an antibody precursor, and may be included as a component of a protein scaffold (eg, a peptide body), a bispecific antibody, or a multispecific antibody having a structure similar to an antibody. .
- heavy chain complementarity determining region a heavy chain complementarity determining region, heavy chain variable region, or nucleic acid molecule encoding a heavy chain of an anti-ICAM-1 antibody.
- nucleic acid molecules encoding light chain complementarity determining regions, light chain variable regions or light chains of anti-ICAM-1 antibodies.
- Another example is a nucleic acid molecule encoding a heavy chain complementarity determining region, heavy chain variable region or heavy chain of the anti-ICAM-1 antibody and a nucleic acid molecule encoding a light chain complementarity determining region, light chain variable region or a light chain of the anti-ICAM-1 antibody.
- Recombinant vectors are provided that are included together or in separate vectors.
- vector means a means for expressing a gene of interest in a host cell.
- viral vectors such as plasmid vectors, cosmid vectors and bacteriophage vectors, adenovirus vectors, retroviral vectors and adeno-associated virus vectors.
- Vectors that can be used as the recombinant vector are plasmids often used in the art (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14) , pQKX1, pQKX2, pGEX series, pET series and pUC19, etc.), phages (e.g., ⁇ gt4 ⁇ B, ⁇ -Charon, ⁇ z1 and M13, etc.) or viruses (e.g., name, SV40, etc.).
- plasmids often used in the art (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8/9, pUC6, pBD9
- the nucleic acid molecule can be operably linked to a promoter.
- operatively linked refers to a functional binding between a nucleotide expression control sequence (eg, promoter sequence) and another nucleotide sequence.
- the regulatory sequence can be "operatively linked” to control transcription and/or translation of other nucleotide sequences.
- the recombinant vector can typically be constructed as a vector for cloning or for expression.
- the expression vector can be used in the art, conventional ones used to express foreign proteins in plants, animals or microorganisms.
- the recombinant vector can be constructed through various methods known in the art.
- the recombinant vector can be constructed using prokaryotic or eukaryotic cells as hosts.
- a prokaryotic cell is a host
- a strong promoter eg, a pL ⁇ promoter, a CMV promoter, a trp promoter, a lac promoter, a tac promoter
- T7 promoter e.g., T7 promoter
- a ribosome binding site for initiation of translation and a transcription/detox termination sequence.
- replication origins that operate on eukaryotic cells included in vectors include f1 replication origin, SV40 replication origin, pMB1 replication origin, adeno replication origin, AAV replication origin, and BBV replication origin, etc. It is not limited.
- a promoter derived from the genome of a mammalian cell eg, a metallothionine promoter
- a promoter derived from a mammalian virus eg, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, Cytomegalovirus promoter and HSV's tk promoter
- a promoter derived from the genome of a mammalian cell eg, a metallothionine promoter
- a promoter derived from a mammalian virus eg, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, Cytomegalovirus promoter and HSV's tk promote
- Another example provides a recombinant cell comprising the recombinant vector.
- the recombinant cell may be obtained by introducing the recombinant vector into an appropriate host cell.
- the host cell is a cell capable of continuously cloning or expressing the recombinant vector while being stable, and any host cell known in the art can be used.
- a prokaryotic cell for example, E. coli JM109, E. coli BL21, E. coli RR1, E. coli LE392, E. coli B, E. coli X 1776, E.
- coli W3110 Bacillus subtilis, Bacillus strains such as Bacillus thuringiensis, and Salmonella typhimurium, Serra Enterobacteria and strains such as Tia Marsensons and various Pseudomonas species, and when transformed into eukaryotic cells, as host cells, yeast ( Saccharomyce cerevisiae ), insect cells, plant cells and animal cells, such as Sp2/0 , CHO (Chinese hamster ovary) K1, CHO DG44, CHO-S, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, MDCK, HEK293 cell line, etc. may be used, but It is not limited.
- a delivery method well known in the art can be used.
- a CaCl 2 method or an electroporation method may be used, and when the host cell is a eukaryotic cell, a micro-injection method, calcium phosphate precipitation method, electroporation method, Liposomal-mediated transfection and gene bombardment may be used, but are not limited thereto.
- the method for selecting the transformed host cell can be easily performed according to a method well known in the art using a phenotype expressed by a selection label.
- the selection marker is a specific antibiotic resistance gene
- the transformant can be easily selected by culturing the transformant in a medium containing the antibiotic.
- Another example provides a method for producing an anti-ICAM-1 antibody, comprising expressing the nucleic acid molecule or a recombinant vector containing the same in a host cell.
- the preparation method may include culturing the recombinant cells containing the recombinant vector, and optionally further comprising the step of isolating and/or purifying the antibody from the culture medium.
- the anti-ICAM-1 antibody or antigen-binding fragment provided herein has the property of binding to domain 2 of human ICAM-1 and inducing antigen-specific T-cell resistance, thereby differentiating and/or dendritic cells. Or it can be useful for the regulation of function and / or prevention and / or treatment for immune cell mediated diseases.
- 2A to 2D are graphs showing the results of quantifying purified antibodies by measuring OD (optical density) at 280 nm in one embodiment.
- 3A to 3D are graphs showing results of measuring a peak symmetry factor by performing size exclusion HPLC (SE-HPLC) analysis on an anti-ICAM-1 antibody obtained according to an embodiment.
- SE-HPLC size exclusion HPLC
- Figures 4a to 4d is a graph showing the results of measuring the change in fluorescence by the ANS reagent while leaving the anti-ICAM-1 antibody obtained according to one embodiment at 61°C for 1 hour.
- 5 is a graph showing the results of measuring the ANS reactivity after leaving the anti-ICAM-1 antibody obtained according to one embodiment at 67°C for 1 hour.
- FIG. 6 is a graph comparing the binding capacity of the anti-ICAM-1 antibody obtained according to an embodiment to the ICAM-1 antigen by ELISA test (y-axis: 450 nm OD value; x-axis: antibody concentration (ng/ml)).
- 7A to 7C are graphs showing melting points of anti-ICAM-1 antibodies obtained according to one embodiment (7a: chimeric antibody, 7b: H17L1, 7c: H17L4).
- FIG. 9 is a heat map graph showing changes in gene expression profiles by humanized antibody administration obtained according to one embodiment in various peripheral blood conditions.
- Figure 10 is a graph showing the analysis of changes in the gene expression profile by administration of the humanized antibody DNP007 obtained according to an embodiment in various peripheral blood conditions for the KEGG pathway (-10 log (adjusted p-value)).
- 11 is a graph showing the analysis of the change in the gene expression profile by administration of the humanized antibody DNP007 obtained according to an embodiment in various peripheral blood conditions for GO Biological process (-10 log (adjusted p-value)).
- 12A and 12B are graphs showing analysis of changes in gene expression profiles by administration of humanized antibody DNP007 obtained according to one embodiment under various peripheral blood conditions by increasing and decreasing cytokine genes.
- FIG. 13 is a graph showing analysis of changes in cytokines by administration of humanized antibody DNP007 obtained according to one embodiment under various peripheral blood conditions with increased and decreased changes in protein levels.
- FIG. 14 is a graph showing analysis of changes in cytokines by administration of humanized antibody DNP007 obtained according to an embodiment under dendritic cells and their T cell co-cultivation conditions with increased and decreased changes in protein levels.
- 15 is a graph showing the degree of maturation cofactor expression of humanized antibody DNP007-treated dendritic cells obtained according to one embodiment.
- 16 is a graph showing the degree of inflammatory cytokine secretion of dendritic cells treated with humanized antibody DNP007 obtained according to an embodiment.
- 17 is a graph showing the degree of apoptosis of humanized antibody DNP007-treated dendritic cells obtained according to one embodiment.
- 18A and 18B are graphs showing the expression levels of the humanized antibody DNP007-treated dendritic cell surface factors obtained according to an embodiment, and show whether or not immune-induced dendritic cells are induced.
- 19A and 19B are graphs showing the degree of IDO (Indoleamine 2,3-Dioxygenase) expression of humanized antibody DNP007-treated dendritic cells obtained according to one embodiment, 19a showing Canonical pathway results, 19b showing Non-canonical pathway results Show each.
- IDO Indoleamine 2,3-Dioxygenase
- FIG. 20 is a graph showing the proliferation degree of T cells cultured with humanized antibody DNP007-treated dendritic cells obtained according to an embodiment and the production of inflammatory cytokine interferon gamma (IFN-r).
- IFN-r inflammatory cytokine interferon gamma
- FIG. 21 shows various dendritic cell maturation pathways for varying degrees of T cell proliferation and production of interferon gamma (IFN-r), an inflammatory cytokine of T cells cultured with humanized antibody DNP007-treated dendritic cells obtained according to one embodiment. It is a graph showing LPS stimulation, TNF-a stimulation, and CD40L stimulation).
- IFN-r interferon gamma
- FIGS. 22A and 22B show arthritis scores before and after administration of the antibody
- FIG. 22C shows anti-collagen antibody levels (22c) respectively.
- FIG. 23A and 23B are results of confirming the graft-versus-host disease inhibitory effect of the humanized antibody DNP007 obtained according to an embodiment in an graft-versus-host disease animal model, and FIG. 22A shows the survival rate and FIG.
- Recombinant human ICAM-1 protein (0.5 mg/ml; NCBI accession number NP_000192.2) was mixed with the same volume of adjuvant (Invivogen, #vac-adx-10) to prepare an immune substance.
- adjuvant Invivogen, #vac-adx-10
- IP 6-week-old Balb/c female mouse intraperitoneal cavity
- the spleen of the immunized mouse was excised as described above to obtain a single cell suspension, washed twice with RPMI (GIBCO, #21875034), and 0.4% (w/v) trypan blue (sigma) 1:1 (v/ After mixing with v), the number of cells was counted by trypan blue (Sigma-aldrich, #T8154) staining.
- the X63 mouse myeloma cell line (ATCC CRL-1580) was washed and counted to be used as a cell fusion partner.
- the bone marrow (myeloma) cells and spleen cells were mixed at a ratio of 1:5 and centrifuged to remove the supernatant.
- 1 ml of 50% (w/v) PEG (polyethylene glycol) 1500 preheated to 37° C. was added slowly over 1 minute. After stagnating for about 1 minute, RPMI medium was slowly added and diluted stepwise.
- ICAM-1 R&D system, #ADP4-050
- PBS PBS
- 1X casein blocking solution Sigma-aldrich, #B6429
- the hybridoma culture solution was dispensed at 100 uL/well and stored in a 37°C incubator for 1 hour to induce an antigen/antibody reaction. After completely removing the culture solution, wash it three times with washing solution (0.02% Tween 20 in PBS), and dilute the secondary antibody Goat anti-mouse IgG-HRP (Jackson, #) in a blocking solution at a ratio of 1:10,000 (v/v). Dispense at 100 uL/well and store in a 37° C. incubator for 30 minutes to induce secondary antibody responses.
- TMB Thermo, #
- 1.0N sulfuric acid H 2 SO 4
- Flow cytometry was additionally performed to confirm whether the obtained anti-ICAM-1 antibody recognizes ICAM-1 expressed on the cell surface.
- Antibody binding was induced by adding 100 uL of culture medium to 1 x 10 6 cells of I145-1 expressing prostate cancer cell line Du145 (ATCC, #HTB-81) and standing at room temperature for 15 minutes.
- the secondary antibody Goat anti-Mouse IgG-FITC (Jackson, #) was diluted in PBS at a ratio of 1:100 (v/v), added to 100 ul, and reacted for 10 minutes at room temperature. After washing, the unreacted secondary antibody was removed and reactivity was confirmed by a flow cytometer.
- a positive antibody that binds to the ICAM-1 antigen was primarily selected, and a monoclonal antibody capable of fluorescent staining was additionally selected for the Du145 cell line.
- the selected monoclonal antibody (named SI9) showed high reactivity to the ICAM-1 protein antigen and effectively binds to the surface of the Du145 cell line.
- the gene of the mouse monoclonal antibody SI9 selected in Example 1 was cloned using a Mouse Ig-Primer Set (Millipore, Cat. #: 69831).
- the monoclonal antibody SI9-producing hybridoma developed in Example 1 was cultured, and total RNA was extracted from the fusion cell line.
- RNA was extracted using a mouse ig-primer set as a template, PCR was inserted into the pGem-T vector (Promega, Cat. #: A3600), and the DNA sequence was confirmed through sequencing. www.imgt.org) to confirm the mouse antibody gene.
- the heavy and light chain variable region amino acid sequences and coding nucleic acid sequences of the analyzed SI9 antibodies are summarized in Table 1:
- an anti-ICAM-1 chimeric antibody was produced.
- plasmids for heavy chain expression and plasmids for light chain expression were prepared, respectively.
- a light chain expression plasmid pOptiVEC (Invitrogen) vector was used, and a heavy chain expression plasmid was made using pcDNA3.3 (Invitrogen) vector.
- variable region coding cDNA and constant region coding cDNA of each antibody in order to express the variable region coding cDNA and constant region coding cDNA of each antibody as a continuous amino acid sequence without additional amino acid insertion, the coding nucleic acid sequence of the cloned variable region (see Table 1) and the known human IgG4 constant region (heavy chain; Each of the genes linking the encoding nucleic acid sequence of GenBank_AIC59040.1) or the encoding nucleic acid sequence of the kappa constant region (light chain; GenBank_AAA58989.1) was synthesized (Bioneer). The "CPSCP" sequence of the middle hinge region of the light chain constant region was further modified with "CPPCP" as in the IgG1 isotype to prevent antibody shuffling.
- the synthesized heavy and light chain expression genes were cut with restriction enzymes Xho I and Sal I, and then the light chain expression gene was ligated to the pOptiVec vector, and the heavy chain expression gene was ligated to the pcDNA3.3 vector to prepare a complete antibody expression plasmid. (pcDNA3.3-anti-ICAM-1 heavy chain expression plasmid and pOptiVEC-anti-ICAM-1 light chain expression plasmid).
- the transformation process was performed by transfection of the produced pcDNA3.3-anti-ICAM-1 heavy chain expression plasmid and pOptiVEC-anti-ICAM-1 light chain expression plasmid into DG44 cells (Invitrogen) derived from CHO cells.
- DG44 cells were cultured in MEMa medium containing 5% FBS to induce adherent cells. Transformation was performed in a 6well plate using ViaFect transfection regent (Promega, Cat.#: E4981).
- ViaFect transfection regent Promega, Cat.#: E4981.
- DG44 cells adapted to adherence were prepared by passage culture at a concentration of 1 X 10 5 cells/well, and the amount of DNA used for transformation was pcDNA3.3-anti-ICAM-1 heavy chain expression plasmid and pOptiVEC.
- -anti-ICAM-1 light chain expression plasmids were used in combination of a 1:2 ratio of 1.0 ⁇ g and 2.0 ⁇ g, respectively. Transformation was performed for 48 hours.
- the transformed cell population was analyzed using a flow cytometer, and the results are shown in FIG. 1. As shown in FIG. 1, it is possible to confirm the binding phenomenon of the ICAM-1 expressing cell line of the chimeric antibody obtained by inserting the variable region coding gene of the mouse SI9 antibody into the constant region coding gene of the human antibody.
- CDRH1 GYTFTDYA (SEQ ID NO: 1)
- CDRH2 ISTYSGNT (SEQ ID NO: 2)
- CDRH3 ARSLYFGSSGFDY (SEQ ID NO: 3)
- CDRL1 QTLVYRNGNTY (SEQ ID NO: 4)
- CDRL2 KVS (SEQ ID NO: 5)
- CDRL3 SQNTHFPYT (SEQ ID NO: 6)
- humanized antibody sequence recombining germline framework region encoding human antibody gene was selected by the in silico method.
- Selected antibody sequences were expressed in HEK293 cells (ATCC CRL-1573) in human IgG4 form by connecting to human IgG4 heavy chain constant region and kappa light chain constant region, respectively.
- the humanized recombinant antibody was purified from the culture medium using KanCap A resin (Kaneca).
- the purified antibody was quantified by measuring the optical density (OD) at 280 nm, and the results are shown in FIGS. 2A to 2D. As shown in Figures 2a to 2d, most of the antibodies prepared regardless of the type of heavy and light chains combined showed relatively high productivity.
- the peak symmetry factor was measured by performing a size exclusion HPLC (SE-HPLC) analysis using a Sepax Zenix-C SEC-300 size exclusion column (Sepax technologies). The obtained results are shown in FIGS. 3A to 3D.
- SE-HPLC size exclusion HPLC
- FIGS. 3A to 3D When a high purity antibody is analyzed by SE-HPLC, it is observed as one symmetric peak, but when a heterogeneous polymer/small molecule is included, two or more peaks are observed or a symmetric peak factor is observed low.
- 3A to 3D in most cases, the anti-ICAM-1 humanized antibody exhibited a relatively high symmetric peak factor.
- humanized antibodies that exhibit resistance to thermal denaturation were selected by leaving the antibody under severe conditions of high temperature and observing changes in physical properties.
- ANS 8-anilino-1-naphthalenesulfonic acid
- Example 96 kinds of humanized recombinant antibodies prepared in Example 2-1 were regularly diluted to a concentration of 0.2 mg/ml using phosphate buffered saline (PBS), and allowed to stand at a high temperature (61° C.) for a suitable time (1 hour).
- 20 uL of 0.2 mg/ml ANS solution was added to 200 uL of the antibody sample, and the mixture was reacted for 15 minutes, and then analyzed under 360 nm excitation and 460 nm emission conditions.
- the 460 nm wavelength emitted by the ANS reaction was measured with a fluorometer (BioTek, SynergyHT) and relative evaluation based on H1L1 antibody (100%) is shown in FIGS. 4A to 4D.
- the 470 nm fluorescence emission by ANS was shown to increase rapidly, and was confirmed to be somewhat denatured by heat, but other antibodies showed relatively heat stability.
- FIGS. 2A-2D, 3A-3D, and 4A-4D a total of 47 humanized antibodies showing relatively high antibody productivity, relatively high peak symmetry factor, and/or relatively high thermal stability under high temperature (61°C) conditions 1 It was selected by car (see FIG. 5).
- the 47 humanized antibodies are constantly diluted to a concentration of 0.2 mg/ml, left at a high temperature of 67° C. for 1 hour, ANS reactivity is measured, and relative reactivity based on H1L1 antibody is shown in FIG. 5. It is shown in. Compared to the ANS reactivity at 61°C (4a to 4d), the ANS reactivity at 67°C tended to be somewhat higher, but the six humanized antibodies of the combination of H17L1, H4L3, H5L3, H11L3, H17L3, and H17L4 ( Table 7) exhibited relatively low ANS reactivity and were evaluated as antibodies with high resistance to heat denaturation.
- Antigen ICAM-1 (ICAM-1; manufactured by R&D system) was coated on a 96 well plate at 100 ng per well, and then blocked. The primary antibody amount was serially diluted from 80 ng/ml twice and bound for 1 hour at a temperature of 37°C. As a secondary antibody, the goat anti-Human Ig-HRP conjugate (Jackson ImmunoResearch) was diluted 1:10000 to 30 at a temperature of 37°C. Combined for a minute. Each step was subjected to a washing process three times and reacted with TMB (3,3',5,5'-Tetramethylbenzidine). After the reaction was stopped by treating the same amount (100ul) with the TMB solution with 1N H 2 SO 4 solution, the OD value was measured at 450 nm.
- TMB 3,3',5,5'-Tetramethylbenzidine
- the binding ability of the parent antibody obtained as described above and the five humanized recombinant antibodies to the ICAM-1 antigen is shown in FIGS. 6 and 8.
- the melting temperatures of the humanized antibodies H17L1 and H17L4 showing stable physical properties were compared with the parent antibody (chimeric antibody; see Example 1.3) to evaluate stability.
- Protein thermal shift dye (Lifetechnologies, #4466038) was added to the antibody sample to prepare a reaction sample, and the temperature was continuously increased from 25°C to 95°C to induce degeneration of the antibody sample. Antibody denaturation was confirmed by measuring the 623 nm wavelength emitted from the protein thermal shift dye by irradiating the reaction solution with a wavelength of 580 nm, and analyzing the melting temperature with ViiA TM 7 software. The results obtained above are shown in Table 9 below and in Figures 7a (chimeric parent antibody), 7b (H17L1) and 7c (H17L4):
- melting temperature 1 was similarly measured at about 67°C for all three antibodies including the chimeric parent antibody, but melting temperature 2 was higher than 10°C in two humanized antibodies compared to the chimeric parent antibody. This means that two humanized antibodies have strong resistance to thermal denaturation compared to chimeric parent antibodies.
- Octet system (ForteBio) was used to compare the affinity of H17L1 and H17L4 humanized antibodies for antigen with the parent antibody.
- Three antibodies were attached to Amine reactive Bio-sensor AR2G (ForteBio) and 5 concentrations of ICAM-1 antigen solution were added to induce an antigen/antibody reaction.
- binding constant (Kon) and dissociation constant (Koff) were measured, and affinity (KD) was calculated, and the results are shown in Tables 10 and 8:
- the affinity (KD) of the chimeric parent antibody was measured to be 1.03 X 10 -8 M, and H17L1 and H17L4 humanized antibodies were 3.43 X 10 -9 and 3.62 x 10 -9 M, respectively. As measured by, it was possible to confirm the improved affinity in the humanized antibody.
- peripheral blood mononuclear cells were treated with the DNP007 antibody (H17L4 antibody) prepared in Example 3 above, and the representative pro-inflammatory cytokine IFN-gamma secretion was measured. Did.
- Blood was collected from normal volunteers, and peripheral blood monocytes were isolated with Ficoll-Paque Plus (GE healthcare, #17144002). Peripheral blood mononuclear cells isolated in 10% FBS-added RPMI medium were suspended, and GM-CSF (Creagene) and IL-4 (Creagene) were added at a concentration of 100 ng/ml to allow dendritic cells to differentiate from monocytes. DNP007 antibody was added to peripheral blood monocytes at a concentration of 10.0 ug/ml.
- Ficoll-Paque Plus GE healthcare, #17144002
- Peripheral blood mononuclear cells isolated in 10% FBS-added RPMI medium were suspended, and GM-CSF (Creagene) and IL-4 (Creagene) were added at a concentration of 100 ng/ml to allow dendritic cells to differentiate from monocytes.
- DNP007 antibody was added to peripheral blood monocytes at a concentration of 10.0 u
- DNP007 antibody to monocytes, which are dendritic cell progenitor cells
- monocytes which are dendritic cell progenitor cells
- the isolated peripheral blood mononuclear cells were cultured for 2 hours in a culture dish to induce adhesion to the culture dish, and then divided into adherent cells and suspended cells, respectively, to divide GM-CSF and IL -4 was added at a concentration of 100 ng/ml, respectively, and DNP007 antibody (10.0 ug/ml) was added together.
- peripheral blood monocytes, adherent cells, and suspended cells were washed and Lipopolysaccharides (LPS, Sigma-Aldrich, #L2630) were added at 5.0 ug/ml to culture.
- LPS Lipopolysaccharides
- the next day's culture was taken to measure the concentration of IFN-gamma secreted by Human IFN gamma Uncoated ELISA kit (Invitrogen, #88-7316-77).
- Peripheral blood monocytes, adherent cells and suspended cells showed a marked decrease in INF-gamma secretion in the sample group treated with DNP007 antibody in all conditions (Table 11). These results were understood as a phenomenon in which the DNP007 antibody inhibits the immune cell activation mechanism by LPS.
- human peripheral blood mononuclear cells are separated and divided into 5 types of peripheral blood groups and divided into 100 ng groups as follows. /ml GM-CSF and 100ng/ml IL-4 were added, and cells were cultured for 6 days under the condition of adding 10 ug/ml of DNP007 antibody to obtain cells, and the cells were cultured on the 6th day for induction into mature dendritic cells.
- PBMC Human peripheral blood mononuclear cells were isolated by performing a concentration gradient centrifugation with blood of healthy volunteers using Ficoll-Paque (GE Healthcare).
- CD14+ monocyte-derived dendritic cells CD14+ monocytes from human peripheral blood mononuclear cells isolated by performing concentration gradient centrifugation with Ficoll-Paque (GE Healthcare) from healthy volunteers using magnetic separation (using magnetic beads) Separated.
- CD14 deplete PBMC CD14+ monocytes of (2) were separated by magnetic separation (using magnetic beads) and the remaining peripheral blood population was used.
- PBMC Human peripheral blood mononuclear cells separated by performing a concentration gradient centrifugation with Ficoll-Paque (GE Healthcare) in healthy volunteers' blood were added to RPMI medium with 10% FBS for 2 hours at 37°C, 5 After attaching the cells in the% CO 2 incubator, the supernatant (including floating cells) was removed and only the attached cells were separated.
- Ficoll-Paque GE Healthcare
- FIG. 9 The results are shown in FIG. 9. As shown in FIG. 9, dendritic cells differentiated from CD14+ monocytes alone (A) and peripheral blood populations not containing CD14+ monocytes (B) showed similar gene expression profiles to the control group not treated with DNP007. On the other hand, in the condition where CD14+-derived dendritic cells are not present alone, but in which several other immune cells are present (C, D, E), the expression pattern of the gene was significantly different from that of the control group not added when DNP007 was added.
- FIGS. 12A and 12B are schematic diagrams of cytokines among distinct genes.
- cytokine gene expression is inhibited by DNP007 antibody treatment.
- the ICAM-1 antibody DNP007 proposed in this specification is not limited to dendritic cells, but affects the process of contact between dendritic cells and other immune cells or cross-reaction between cells, through which It can be seen that the response gene expression is regulated, resulting in an immunosuppressive response.
- sample administered with DNP007 antibody was also remarkably immune cytokine protein as shown in FIG. 14, even when it was separated into normal human blood and differentiated into dendritic cells, and when LPS treatment was induced by co-culture with T cells of the same person, LPS treatment was induced. Expression inhibition at the level was confirmed.
- CD80 Invitrogen, Catalog# 11-0809-42
- CD86 BD, Catalog# 555657
- CD40 BD, Catalog# 555588
- CD54 BD, Catalog# 347977
- HLA-DR BioLegend, Catalog# 307616
- each obtained factor (Mean of Fluorescent Intensity, MFI) was converted to a relative value for the group treated with LPS only, and is shown in FIG. 15. 15, in the case of dendritic cells treated with a control antibody (hIgG), expression of cofactors such as CD80, CD54, CD40, and HLA-DR was increased by LPS stimulation, but the test antibodies DNP007 and LPS were increased. In the group treated together, it was confirmed that the expression of these cofactors was significantly reduced.
- human peripheral blood monocytes isolated from peripheral blood are cultured for 5 days with GM-CSF and IL-4 to differentiate into dendritic cells, and LPS After inducing maturation by incubating the same stimulating factor and incubating for 24 hours, the amount of inflammatory cytokines in the culture medium was analyzed to measure the maturity of dendritic cells.
- human peripheral blood monocytes were isolated using a cell collection device (Miltenyi Biotec. Cat. 000403).
- Differentiation was induced into immature dendritic cells (immature DC) for 5 days by adding 10% FBS-containing RPMI culture treated with GM-CSF and IL-4 at a concentration of 100 ng/ml, respectively.
- immature dendritic cells Immature DC
- FBS-containing RPMI culture treated with GM-CSF and IL-4 at a concentration of 100 ng/ml, respectively.
- 5 ug/ml of LPS was added and stimulation of dendritic cells (mature DC) for 24 hours was induced to differentiate into mature dendritic cells.
- Antibodies DNP007 H17L4 antibody
- control antibody hIgG, provided herein
- inflammatory cytokines in culture Proinflammatory cytokine
- IL-6 and TNF-a were analyzed using ELISA technique.
- Dendritic cell maturation refers to a process in which dendritic cells acquire an ability as antigen-presenting cells, and mature dendritic cells function to induce the activity of antigen-specific T cells.
- the degree of death of dendritic cells differentiated and matured for 6 days according to the antibody treatment was measured.
- the degree of apoptosis was confirmed by flow cytometry after 7AAD staining.
- human peripheral blood monocytes were isolated using a cell collection device (Miltenyi Biotec. Cat. 000403). Differentiation was induced to immature dendritic cells (immature DC) for 5 days by adding RPMI culture containing 10% FBS treated with GM-CSF and IL-4 at a concentration of 100 ng/ml, respectively. On day 5 of culture, 5 ug/ml of LPS was added, and mature dendritic cells were differentiated by stimulating dendritic cells (mature DC) for 24 hours.
- the antibody DNP007 H17L4 antibody
- the control antibody hIgG
- 7AAD 7-Amino-Actinomycin D, BD, 51-68981E 5ul/test
- the apoptotic effect of dendritic cells by the test antibody may be evaluated as apoptosis.
- the antibody DNP007 H17L4 antibody
- the control antibody hIgG
- the dendritic cell differentiation induction process was added twice at a concentration of 5.0 ug/mL on day 0 and 3, and on the 6th day after induction of differentiation, expression of the dendritic cell marker factor for immune tolerance was confirmed by a flow cytometer.
- Cell fluid substances IDO Indoleamine 2,3-Dioxygenase; Invitrogen, Catalog# 12-9477-42
- TGF- ⁇ R&D systems, Catalog# IC240P
- IL-10 Miltenyi biotec, Catalog# 130-112-729
- IC Fixation buffer Invitrogen, Catalog# 00-8222-49
- 1x Permeabilization buffer (Invitrogen, Catalog# 00-8333-56) was added, centrifuged at 600 g for 5 minutes, and the supernatant was removed. The remaining cell pellet was prepared by adding the appropriate concentration of each antibody to 100 ul of 1x Permeabilization buffer, treated with cells, blocked the light at room temperature, and reacted for 30 minutes. 2 mL of 1x Permeabilization buffer was added, washed by centrifugation at 600 g for 5 minutes, and 2 ml of flow cytometry buffer was added and centrifuged to perform further washing. Cells were fixed by adding 1% paraformaldehyde, and the expression level of each antigen was analyzed using a flow cytometer.
- FIGS. 18A and 18B The obtained results are shown in FIGS. 18A and 18B.
- the test antibody DNP007-treated dendritic cells showed a significant increase in expression of IDO, a representative factor for immune tolerance, compared to the control antibody-treated dendritic cells (control), and other immunosuppressive factors.
- the expression levels of known PDL1, PDL2 and adenosine R A2b were also increased compared to the control group.
- the expression of some factors related to IDO and immune tolerance increased.
- IDO expressed in dendritic cells is known to inhibit the proliferation of T cells and play an important role in immune tolerance.
- increased IDO expression by the antibodies provided herein suggests a high likelihood that immune tolerance will be induced.
- LPS and CD40L were used to induce maturation of dendritic cells.
- IDO a dendritic cell marker for immune tolerance
- Example 5-2 or 5-3 stimulation by LPS known as the Canonical pathway was performed under the same conditions as in Example 5-2 or 5-3 to prepare and test semi-mature dendritic cells that have undergone differentiation and maturation processes for 6 days.
- CD40L In the stimulation test by CD40L, known as the non-canonical pathway, immature dendritic cells differentiated for 5 days with 10% FBS containing RPMI culture treated with GM-CSF and IL-4 at a concentration of 100 ng/ml were used. On the 5th day after cultivation, 1 ug/ml of CD40L (Enzo, ALX-522-110) was added to 10% FBS containing RPMI treated at a concentration of 100 ng/ml of GM-CSF and IL-4 to give 48 hours of stimulation. Mature dendritic cells (mature DC) were induced.
- CD40L Enzo, ALX-522-110
- the antibody DNP007 H17L4 antibody
- the control antibody hIgG
- Treatment On the seventh day of induction of differentiation, mature dendritic cells (Mature DC) were stained using the intracellular antigens mentioned above (Staining intracellular Antigens) and analyzed using a flow cytometer.
- 19A and 19B the test antibody DNP007 induces a decrease in the expression of IDO in cells during the process of maturation of dendritic cells by CD40L, whereas maturation of dendritic cells by LPS shows a large difference in IDO expression between individuals.
- the dendritic cell maturation pathways include the classical pathway induced by LPS and TNF-a stimulation and the non-classical pathway induced by CD40L.
- the results show that the antibodies provided herein affect both dendritic cell maturation pathways, in particular limiting maturation by CD40L and inducing differentiation into immune-tolerant dendritic cells.
- the dendritic cells and T cells are used.
- the cells were cultured under isolated conditions, and the activity of T cells was inhibited.
- CD3 microbead Motenyi, 130-050-201
- human T cells isolated using a cell collection device and obtained under the same conditions as Examples 5-1 to 5-5 were obtained.
- Mature dendritic cells Mature DC
- autologous T cells were subjected to CFSE labeling as a condition to confirm proliferation.
- differentiated dendritic cells were put by treating the antibody DNP007 (H17L4 antibody) provided herein.
- the two cells were cultured for 4 days while sharing the culture medium in each chamber.
- the number of dendritic cells and autologous T cells was treated at a ratio of 1:10.
- FIG. 20 The obtained results are shown in FIG. 20.
- proliferation was inhibited by the test antibody-treated dendritic cells, and the production of inflammatory cytokine interferon gamma (IFN-r) was reduced.
- IFN-r inflammatory cytokine interferon gamma
- the activity and proliferation of T cells was confirmed under conditions in which dendritic cells and T cells were cultured together.
- the maturation of dendritic cells was induced using LPS, TNF-a and CD40L, which are stimulators of two known mature pathways, and the proliferation of T cells and the expression level of inflammatory cytokines in the cells were measured.
- dendritic cell maturation was induced using two known pathways (Canonical pathway: LPS, TNF-alpha/Non-canonical pathway: CD40L), respectively.
- Stimulation with LPS and CD40L was performed in the same manner as in Example 5-5, and stimulation with TNF-alpha was 100 ng/ GM-CSF and IL-4 on Day 5, respectively, in the state induced by immature dendritic cells.
- TNF-a 13 ng/ml, IL-1 ⁇ 10 ng/ml, and PGE2 350 ng/ml were treated with 10% FBS containing RPMI treated at ml concentration, and stimulated for 48 hours to differentiate into mature dendritic cells (mature DC). Proceeded.
- the antibody DNP007 (H17L4 antibody) and the control antibody (hIgG) provided herein were treated twice at a concentration of 5.0 ug/ml on day 0 and 3 during the process of inducing dendritic cell differentiation.
- T cells To induce the activity of T cells, 1 ⁇ g/ml of anti-CD3 antibody was added to the plate with mature dendritic cells and autologous T cells differentiated in the same manner as above. The expression level of inflammatory cytokines in the cells was measured. At this time, CFSE labeling was performed to confirm the proliferation of T cells.
- T cells cultured with dendritic cells treated with a control antibody showed vigorous cell proliferation, and highly expressed IFN- ⁇ and IL-10, which are representative of inflammatory cytokines.
- T cells cultured with dendritic cells with limited maturation by treatment with test antibody DNP007 inhibited proliferation despite stimulation by anti-CD3 antibody and markedly reduced inflammatory cytokine secretion.
- T cells sensitized by dendritic cells have been shown to limit proliferation and expression of inflammatory cytokines. That is, the semi-mature dendritic cells induced by the antibodies provided herein suppress the activity and proliferation of T cells.
- graft-versus-host disease is one of the side effects of transplanted patients (recipients) when transplanting allogeneic organs (e.g., bone marrow), where donor T cells or NK cells don't It is a phenomenon that appears by attack.
- allogeneic organs e.g., bone marrow
- donor T cells or NK cells don't It is a phenomenon that appears by attack.
- PBMC peripheral blood mononuclear cells
- a graft-versus-host disease (GVHD) model was established by irradiating NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) female mice with 1.6 Gy and then injecting human PBMC.
- Human PBMC was obtained by centrifugation using Ficoll (GE Healthcare, 17544202) in a Leucosep TM tube (Greiner bio-one, 227290) and separating the intermediate white layer.
- the isolated human PBMCs were administered intraperitoneally at 1 ⁇ 10 7 cells/200 ⁇ L per mouse.
- the test group was prepared by administering the antibody DNP007 (H17L4 antibody) provided herein at a dose of 10 mg/kg twice a week for 6 weeks, and CTLA-4-Ig (Bio X cell, BE0099) 10 mg/kg
- a positive control group was prepared by administering 12 doses twice a week for 6 weeks in total.
- the measurement of GVHD induction and treatment effect was recorded by scoring five clinical criteria (weight loss, behavior, activity, hair loss, skin; weight loss, posture, activity, fur, skin).
- FIGS. 23A and 23B The obtained results are shown in FIGS. 23A and 23B.
- the test group (G4) administered with the antibody provided in the present specification significantly improved the survival rate than the negative control group G2 (FIG. 23A), and that human T cells were reorganized normally (FIG. 23B).
- the antibody provided herein has an effect of preventing graft-versus-host disease occurring during allogeneic bone marrow transplantation and enabling re-establishment of normal donor T cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (15)
- 다음의 상보성 결정부위 (complementarity determining region; CDRs)를 포함하는, 항 ICAM-1 항체 또는 이의 항원 결합 단편:서열번호 1의 아미노산 서열을 포함하는 CDR-H1,서열번호 2의 아미노산 서열을 포함하는 CDR-H2,서열번호 3의 아미노산 서열을 포함하는 CDR-H3,서열번호 4의 아미노산 서열을 포함하는 CDR-L1,서열번호 5의 아미노산 서열을 포함하는 CDR-L2, 및서열번호 6의 아미노산 서열을 포함하는 CDR-L3.
- 제1항에 있어서, 프레임워크로서 다음을 포함하는, 항 ICAM-1 항체 또는 이의 항원 결합 단편:서열번호 97 또는 98의 아미노산 서열을 포함하는 중쇄 프레임워크 1;서열번호 99 또는 100의 아미노산 서열을 포함하는 중쇄 프레임워크 2;서열번호 101 또는 102의 아미노산 서열을 포함하는 중쇄 프레임워크 3;서열번호 81의 아미노산 서열을 포함하는 중쇄 프레임워크 4;서열번호 103 또는 104의 아미노산 서열을 포함하는 경쇄 프레임워크 1;서열번호 105의 아미노산 서열을 포함하는 경쇄 프레임워크 2;서열번호 106의 아미노산 서열을 포함하는 경쇄 프레임워크 3; 및서열번호 107의 아미노산 서열을 포함하는 경쇄 프레임워크 4.
- 제1항에 있어서, 프레임워크로서 다음을 포함하는, 항 ICAM-1 항체 또는 이의 항원 결합 단편:서열번호 39, 40, 41, 42, 43, 44, 45, 46, 47, 및 48 중에서 선택된 아미노산 서열을 포함하는 중쇄 프레임워크 1;서열번호 49, 50, 51, 52, 53, 54, 및 55 중에서 선택된 아미노산 서열을 포함하는 중쇄 프레임워크 2;서열번호 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 및 80 중에서 선택된 아미노산 서열을 포함하는 중쇄 프레임워크 3;서열번호 81의 아미노산 서열을 포함하는 중쇄 프레임워크 4;서열번호 82, 83, 및 84 중에서 선택된 아미노산 서열을 포함하는 경쇄 프레임워크 1;서열번호 85, 86, 87, 88, 및 89 중에서 선택된 아미노산 서열을 포함하는 경쇄 프레임워크 2;서열번호 90, 91, 및 93 중에 선택된 아미노산 서열을 포함하는 경쇄 프레임워크 3; 및서열번호 93 또는 94의 아미노산 서열을 포함하는 경쇄 프레임워크 4.
- 제1항에 있어서,서열번호 7 및 11 내지 34로 이루어진 군에서 선택된 아미노산 서열을 포함하는 중쇄 가변영역; 및서열번호 8 및 35 내지 38로 이루어진 군에서 선택된 아미노산 서열을 포함하는 경쇄 가변영역을 포함하는, 항 ICAM-1 항체 또는 이의 항원 결합 단편.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 항 ICAM-1 항체는 동물 항체, 키메릭 항체, 또는 인간화 항체인, 항 ICAM-1 항체 또는 이의 항원 결합 단편.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 항원 결합 단편은 상기 항 ICAM-1 항체의 scFv, (scFv)2, Fab, Fab', 또는 F(ab')2인, 항 ICAM-1 항체 또는 이의 항원 결합 단편.
- 제1항 내지 제4항 중 어느 한 항의 항 ICAM-1 항체 또는 이의 항원 결합 단편을 포함하는, 면역세포 매개성 질환의 예방 또는 치료용 약학 조성물.
- 제7항에 있어서, 상기 면역세포 매개성 질환은 이식거부, 이식편 대 숙주 질환, 천식, 비만, 제2형 당뇨병, 면역세포 매개 염증, 또는 자가면역질환인, 약학 조성물.
- 제8항에 있어서, 상기 자가면역질환은 뇌척수염, 류마티스 관절염, 전신홍반성 낭창, 아토피 피부염, 다발성 경화증, 1형 당뇨병, 크론병, 궤양성 대장염, 베체트병, 쇼그렌증후군, 중증근무력증, 경피증, 결정성 다발동맥염, 기쿠치병, 교원병, 하시모코 갑상선염, 건선, 백반증, 갑상선 기능 항진증, 섬유근육통, 원형탈모, 또는 알러지인 약학 조성물.
- 서열번호 1 내지 6 중에서 선택된 아미노산 서열을 암호화하는 핵산 분자.
- 서열번호 7 및 11 내지 34 중에서 선택된 아미노산 서열;서열번호 8 및 35 내지 38에서 선택된 아미노산 서열; 또는이들 모두를 암호화하는 핵산 분자.
- 제10항 또는 제11항의 핵산 분자를 포함하는 재조합 벡터.
- 제12항의 재조합 벡터를 포함하는 재조합 세포.
- 제13항의 재조합 세포를 배양하는 단계를 포함하는, 항 ICAM-1 항체 또는 이의 항원 결합 단편의 제조 방법.
- 제1항 내지 제4항 중 어느 한 항의 항 ICAM-1 항체 또는 이의 항원 결합 단편을 포함하는, ICAM-1 검출용 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980087502.3A CN113272328B (zh) | 2018-12-31 | 2019-12-31 | 与icam-1特异结合的抗体及其用途 |
EP19907470.9A EP3909979A4 (en) | 2018-12-31 | 2019-12-31 | ANTIBODIES SPECIFIC TO ICAM-1 BINDING AND USE THEREOF |
AU2019419832A AU2019419832B2 (en) | 2018-12-31 | 2019-12-31 | Antibody specifically binding to ICAM-1 and use thereof |
JP2021538358A JP7308957B2 (ja) | 2018-12-31 | 2019-12-31 | Icam-1に特異的に結合する抗体およびその用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180173725A KR102063341B1 (ko) | 2018-12-31 | 2018-12-31 | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
KR10-2018-0173725 | 2018-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020141869A1 true WO2020141869A1 (ko) | 2020-07-09 |
Family
ID=69153585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/018822 WO2020141869A1 (ko) | 2018-12-31 | 2019-12-31 | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3909979A4 (ko) |
JP (1) | JP7308957B2 (ko) |
KR (1) | KR102063341B1 (ko) |
CN (1) | CN113272328B (ko) |
AU (1) | AU2019419832B2 (ko) |
WO (1) | WO2020141869A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230059469A (ko) * | 2021-10-26 | 2023-05-03 | 재단법인 아산사회복지재단 | 암 생존자 유래 항체 및 이의 용도 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016927A1 (en) * | 1990-04-27 | 1991-11-14 | Celltech Limited | Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof |
KR20080090532A (ko) * | 2006-01-26 | 2008-10-08 | 에이치엑스 디아그노스틱스, 인크. | 조류 인플루엔자 바이러스 서브타입 h5 헤마글루티닌에 결합하는 모노클로날 항체 및 그의 용도 |
KR20110023897A (ko) * | 2008-08-08 | 2011-03-08 | 다이노나(주) | 세포간 부착분자-1 과의 결합을 통하여 수지상 세포의 기능 및 분화를 조절하는 항체 및 이의 용도 |
KR20140026567A (ko) * | 2011-07-05 | 2014-03-05 | 다이노나(주) | 항원-특이적 세포 내성을 유도하는 항체 및 이의 용도 |
US20180221482A1 (en) * | 2013-01-09 | 2018-08-09 | Bioinvent International Ab | Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004060919A1 (ja) * | 2002-12-26 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | ヘテロ受容体に対するアゴニスト抗体 |
WO2005086568A2 (en) * | 2004-01-26 | 2005-09-22 | Morphosys Ag | Anti-icam-1 human antibodies and uses thereof |
WO2007091719A1 (ja) * | 2006-02-07 | 2007-08-16 | Mochida Pharmaceutical Co., Ltd. | 抗gpvi抗体の併用療法及び新規医薬用途 |
JP5382692B2 (ja) * | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
KR101434029B1 (ko) * | 2012-09-14 | 2014-08-26 | 서울대학교산학협력단 | Icam-1에 대한 항체 및 그 용도 |
MX2019002742A (es) * | 2016-09-08 | 2019-05-09 | Daiichi Sankyo Co Ltd | Anticuerpo para el tratamiento de enfermedades autoinmunes. |
-
2018
- 2018-12-31 KR KR1020180173725A patent/KR102063341B1/ko active IP Right Review Request
-
2019
- 2019-12-31 WO PCT/KR2019/018822 patent/WO2020141869A1/ko unknown
- 2019-12-31 CN CN201980087502.3A patent/CN113272328B/zh active Active
- 2019-12-31 EP EP19907470.9A patent/EP3909979A4/en active Pending
- 2019-12-31 AU AU2019419832A patent/AU2019419832B2/en active Active
- 2019-12-31 JP JP2021538358A patent/JP7308957B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991016927A1 (en) * | 1990-04-27 | 1991-11-14 | Celltech Limited | Humanized cdr-grafted anti-icam-1 antibodies, methods of preparation and usage thereof |
KR20080090532A (ko) * | 2006-01-26 | 2008-10-08 | 에이치엑스 디아그노스틱스, 인크. | 조류 인플루엔자 바이러스 서브타입 h5 헤마글루티닌에 결합하는 모노클로날 항체 및 그의 용도 |
KR20110023897A (ko) * | 2008-08-08 | 2011-03-08 | 다이노나(주) | 세포간 부착분자-1 과의 결합을 통하여 수지상 세포의 기능 및 분화를 조절하는 항체 및 이의 용도 |
KR20140026567A (ko) * | 2011-07-05 | 2014-03-05 | 다이노나(주) | 항원-특이적 세포 내성을 유도하는 항체 및 이의 용도 |
US20180221482A1 (en) * | 2013-01-09 | 2018-08-09 | Bioinvent International Ab | Use of antibodies against icam-1 in combination with an anti cancer drug in the treatment of patients |
Non-Patent Citations (7)
Title |
---|
"NCBI", Database accession no. NP_001266532 |
ARTHRITIS RHEUM, vol. 37, 1994, pages 992 - 999 |
J IMMUNOL, vol. 144, 1990, pages 4604 - 4612 |
J IMMUNOL, vol. 162, 1999, pages 2352 - 2357 |
J RHEUMATOL, vol. 23, 1996, pages 1338 - 1344 |
PROC NATL ACAD SCI USA, vol. 85, 1988, pages 3095 - 3099 |
See also references of EP3909979A4 |
Also Published As
Publication number | Publication date |
---|---|
EP3909979A4 (en) | 2022-09-14 |
JP2022518363A (ja) | 2022-03-15 |
CN113272328B (zh) | 2024-05-14 |
AU2019419832B2 (en) | 2023-12-14 |
JP7308957B2 (ja) | 2023-07-14 |
AU2019419832A1 (en) | 2021-07-22 |
KR102063341B1 (ko) | 2020-01-07 |
EP3909979A1 (en) | 2021-11-17 |
CN113272328A (zh) | 2021-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11053298B2 (en) | Epitope for switching to TH2 cell and use thereof | |
JP2022106950A (ja) | モノクローナル抗IL-1RAcP抗体 | |
WO2020111913A1 (en) | Anti-4-1bb antibody and use thereof | |
WO2019098682A1 (ko) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 | |
JP6621778B2 (ja) | IL7受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用 | |
KR102003075B1 (ko) | 인간 il33r에 대한 항체 및 이의 용도 | |
WO2015058573A1 (zh) | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 | |
WO2021006619A1 (ko) | B7-h3에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2018222019A1 (ko) | 신규한 항-cd40 항체 및 이의 용도 | |
WO2020141869A1 (ko) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 | |
US11905331B2 (en) | Antibody binding specifically to CD40 and use thereof | |
WO2022177392A1 (ko) | Cd47에 대한 단일 도메인 항체 및 이의 용도 | |
WO2023234748A1 (ko) | 항-tigit 항체 및 이의 용도 | |
RU2789757C2 (ru) | Антитело, специфично связывающееся с icam-1, и его применение | |
WO2023239226A1 (ko) | Tigit에 특이적으로 결합하는 항체 및 인터류킨-15를 포함하는 융합 단백질 및 이의 용도 | |
WO2022250502A1 (en) | Ox40 agonist and use thereof | |
WO2023132719A1 (ko) | Cd40l에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2022216079A1 (ko) | Gucy2c 결합 폴리펩타이드 및 그의 용도 | |
WO2021029746A2 (ko) | 항-tie2 항체 및 이의 용도 | |
WO2022139537A2 (ko) | 뮤신 1에 특이적인 폴리펩티드 및 이의 이용 | |
WO2022098173A1 (ko) | 코로나바이러스 스파이크 단백질에 특이적인 항체 및 이의 용도 | |
WO2021118246A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof | |
WO2021132746A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof | |
WO2019194314A1 (ja) | Spns2中和抗体 | |
TW202412852A (zh) | 人類腫瘤壞死因子α抗體糖皮質激素結合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19907470 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021538358 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019419832 Country of ref document: AU Date of ref document: 20191231 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019907470 Country of ref document: EP Effective date: 20210802 |